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Dear Editor:
A review by Olivera and colleagues compared five South 
American clinical practice guidelines for Chagas disease, 
assessing quality using the Appraisal of Guidelines Research 
and Evaluation (AGREE II) method1. The analysis determined 
the overall quality of the guidelines issued by ministries of 
health or professional associations prior to 2016, which ranged 
from low to moderate. The authors noted that these guidelines 
did not have a strong connection to the best available evidence. 
Since the period covered by the analysis, new evidence 
has come to light. The results of the BENEFIT trial were 
published in the last quarter of 2015, suggesting that treatment 
with benznidazole in older adults with moderate to severe 
cardiomyopathy was no more effective than placebo2. However, 
the trial’s results underscore the importance of providing 
etiological treatment before the onset of cardiomyopathy. Along 
with other recently concluded studies, this study contributed new 
evidence supporting the antiparasitic efficacy of the drug3-5. Other 
evidence suggests that treatment with benznidazole prevents 
future congenital transmission6-9. 
Additionally, reiterating a point made by Novaes and 
Silvestre10, important clinical practice guidelines have emerged 
since 2015. Argentina’s guidelines were updated in 2015; in 2016, 
Médecins sans Frontières/Doctors without Borders produced a 
manual on treatment of Chagas disease based on its experience 
in rural Bolivia; and the Second Brazilian Consensus on Chagas 
Disease was published11-13. These guidelines make stronger 
recommendations in favor of treatment in the chronic indeterminate 
phase. The 2015 Argentinian guidelines and the Brazilian 
Consensus contain clear evidence-based recommendations, 
which Olivera et al. noted was a weakness of the earlier 
guidelines that they reviewed. The Brazilian Consensus provides 
recommendations for etiological treatment linked to strength of 
evidence; treatment of adults in the chronic indeterminate phase 
is considered a Class IIa recommendation (Evidence Level B). 
Another important development is the recent publication of 
clinical guidelines by the Pan American Health Organization14.
In August 2017, the Chagas Clinical Research Platform 
conducted a workshop15 at the Annual Meeting of the Brazilian 
Society of Tropical Medicine, which compared guidelines/
recommendations for treatment of Chagas disease in Brazil, 
Argentina, and Colombia11,12,16.* The three countries’ guidelines 
showed general agreement on considering etiological treatment 
for adults in the chronic indeterminate phase; initiating 
diagnosis and etiological treatment through the primary care 
level; monitoring during drug therapy, using complete blood 
count and tests of renal and hepatic function; and implanting 
defibrillators for cases of conduction system damage. There 
was also concordance on the need to set a maximum limit 
for the daily dose of benznidazole (400 mg/day in Argentina, 
and 300 mg/day in Brazil and Colombia). However, the 
guidelines continued to differ in terms of diagnostic procedures, 
frequency of monitoring during treatment, handling of treatment 
suspension due to adverse reactions, criteria for retreatment, and 
provision of pre- and post-treatment consultations. 
Olivera et al.’s assertion that inconsistency in guidelines 
can create a potential barrier to treatment is still valid. 
Nevertheless, there is now a stronger tendency to use evidence-
based guidelines that favor offering treatment to adults with 
*Marisa Fernandez (Argentina), Alejandro Luquetti and Veruska Maia da 
Costa (Brazil), and Rafael Herazo (Colombia) prepared and/or presented the 
information in the workshop. See:
https://www.dndial.org/wp-content/uploads/2018/06/Consensustable_COL_BRA_ARG_ENG.pdf. 
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indeterminate chronic infection. Further, the need for greater 
clarity regarding diagnosis, assessment of treatment efficacy (or 
failure), dosage and monitoring of benznidazole and nifurtimox, 
and use of ace inhibitors and beta blockers for chronic Chagas 
cardiomyopathy remains. Future advancement in these areas 
hinges on ongoing clinical research, and will be especially 
enhanced by improved understanding of biomarkers. Use of the 
GRADE methodology to update various countries’ guidelines 
in the future would be one way to reinforce consistency. 
While new evidence has strengthened recent clinical practice 
guidelines, substantial work is required to ensure that evidence-
based recommendations are utilized consistently and appropriately 
in the various countries where Chagas disease is a public health 
concern10. Indeed, there will be some heterogeneity in guidelines 
due to the unique, context-specific challenges in each country, 
which stem not only from regional variation in the characteristics 
of T. cruzi-induced pathology, but also from differences in the 
organization of public health systems and the needs of patient 
populations. At present, with few people with Chagas disease 
receiving any form of diagnosis or treatment, clinicians’ lack 
of awareness of up-to-date treatment recommendations poses 
a major point-of-entry barrier for patients. Effective guidelines 
are but one component, which, in conjunction with greater 
investment in public health programs, improved safety and efficacy 
of drug therapy, better diagnostics and markers of treatment 
efficacy, expanded provider and public education initiatives, 
and affirmation of healthcare as a universal human right, can 
begin to turn back the global tide of neglect of Chagas disease. 
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